Tevogen Bio To Discusses Its Genetically Unmodified T Cell Technology For The Treatment of Infectious Diseases, Cancers, And Neurological Disorders With Nasdaq's Kristina Ayanian

Author: Benzinga Newsdesk | July 10, 2024 08:16am

• Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applications
• Tevogen's ExacTcell™ platform is designed to address current cost, and patient accessibility challenges
• ExacTcell's first product consists of single HLA restricted, off-the-shelf, genetically unmodified T cells
• Broad application potential spanning cancer, infectious diseases, and neurological disorders
• ExacTcell platform produced hundreds of doses from a single donor, facilitating cost reduction
  
   

WARREN, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Dr. Neal Flomenberg and Dr. Lori Grosso of Tevogen Bio Holding Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, discussed the promise of T cell therapy and Tevogen's mission to make it mainstream on Nasdaq's broadcast, Live From MarketSite with Kristina Ayanian.

Posted In: TVGN